Merck KGaA announced in December the top-line results of its failed phase III trials of evobrutinib, a first-in-class Bruton’s tyrosine kinase (BTK) inhibitor, but few details were available at that time. Full results have now been presented by Dr. Xavier Montalban, Barcelona, Spain, at the ACTRIMS Forum conference, held February 29-March 2 in West Palm Beach, Florida. Read More
Latest News
ACTRIMS 2024 survey
February 28, 2024Help make the NeuroSens coverage of the ACTRIMS Forum 2024 relevant to you.
Complete the survey below to tell us what topics are of greatest interest to you. Read More
New consensus statement on MRI biomarkers in MS
February 20, 2024The North American Imaging in Multiple Sclerosis (NAIMS) cooperative has issued a consensus statement on chronic active lesions (CAL) in MS and how biomarkers may be employed to evaluate them (Bagnato et al. Brain 2024; epublished January 16, 2024). Read More
No benefit with adjuvant vitamin D in MS: meta-analysis
February 12, 2024A new meta-analysis (9 studies, N=867) has concluded that high-dose vitamin D3 supplementation does not have a significant impact on clinical outcomes in patients with MS (Mahler et al. Mult Scler Relat Disord 2024:82:105433). Read More